EGFR and non-small cell lung carcinoma: Findings from the SLR also indicated that patients with advanced NSCLC and the Exon 20ins mutation have poorer treatment outcomes compared with patients with other EGFR mutations and EGFR WT across different therapy options and treatment lines.